As healthcare costs continue to rise, biosimilars offer new therapeutic options with the potential for cost savings to the healthcare system. With anticipated savings, biosimilars bring hope that there will be expanded access for patients to not only these known therapies, but also to new innovative medicines. At Amgen, serving patients is at the core of what we do and it is why we’re using our more than 35 years of biologics experience to develop high-quality biosimilars.

It is currently estimated that $90 billion in global sales of biologic medicines will go off patent by 2020. Even modest reductions in cost of these products would have meaningful impact to healthcare systems around the world. While biologic medicines have revolutionized treatment of patients suffering from serious diseases like inflammatory bowel disease (IBD), rheumatoid arthritis, psoriasis, hepatitis C, diabetes and various cancers, the cost of treatment with these products can reach at least $21,000+1 per patient annually. Because the cost to develop and manufacture biosimilars, particularly high-quality biosimilars, is considerably higher than for small molecule generics, cost reductions are expected to be more modest for biosimilars than what is sometimes realized for small molecule generics.

I am interested in biosimilars and would like to learn more:

To become informed about the use of biosimilars, patients and healthcare providers can explore the following topics:

  • How are biosimilars different from generics? LEARN MORE
  • Why is it important to track and trace the use of biosimilars in patients? LEARN MORE
  • Is the patient getting the right medicine prescribed by the physician? LEARN MORE
  • Why will biosimilars differ from each other and from the reference product? LEARN MORE
  • What are the manufacturing processes and quality control systems to develop high quality biosimilars? LEARN MORE
  • As a healthcare provider, why should I understand the analytical data for a biosimilar? LEARN MORE
  • As a healthcare provider, how can I assess the “totality of evidence” before prescribing a particular biosimilar? LEARN MORE

What are Biosimilars?

Amgen's Commitment to Biosimilars

Amgen's Biosimliar Portfolio